Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones

On November 6, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, reported its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany, with additional digital partnering sessions scheduled for November 17–18. BIO-Europe 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sari Fishman, Vice President of Business Development, will represent Can-Fite at the conference, focusing on potential licensing agreements, co-development arrangements, commercialization partnerships, and other strategic transactions aimed at unlocking the commercial value of the Company’s advanced clinical pipeline.

Can-Fite enters BIO-Europe following a series of clinical and intellectual property developments that have strengthened its portfolio and expanded potential partnering opportunities across multiple therapeutic areas.

Key assets and partnering opportunities include:

• Namodenoson – Pancreatic Cancer: Final positive Phase IIa results, presented at ESMO (Free ESMO Whitepaper) 2026, demonstrated a favorable safety profile and encouraging exploratory survival findings in heavily pretreated patients, supporting further clinical development.

• Namodenoson – Liver Cancer: An ongoing pivotal Phase III study in advanced hepatocellular carcinoma (HCC), with longer-than-anticipated blinded overall survival observed across the study population. An interim analysis is planned.

• Piclidenoson – Psoriasis: A pivotal Phase III program that has reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.

• Namodenoson – MASH: An ongoing Phase IIb clinical development program targeting a significant global market opportunity.

• Piclidenoson – Lowe Syndrome: A rare disease development program supported by a collaboration with Fondazione Telethon and recently strengthened by a Eurasian patent allowance covering Lowe syndrome and Dent disease 2.

Can-Fite has already established multiple regional licensing agreements, generating approximately $20 million in upfront and milestone payments to date, with the potential for additional milestones and royalties. The Company intends to build on this commercial track record by pursuing additional regional and broader strategic partnerships.

"BIO-Europe provides an important opportunity to translate our recent clinical and intellectual property progress into strategic business discussions," said Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma. "With two pivotal Phase III programs, encouraging new clinical data in pancreatic cancer, and an expanding portfolio of development and commercialization opportunities, we believe Can-Fite offers potential partners access to differentiated clinical-stage assets across several major therapeutic markets. Our objective is to pursue licensing and strategic collaborations that can accelerate development, expand global commercialization opportunities, and create long-term value for our shareholders."

BIO-Europe is one of the biopharmaceutical industry’s leading international partnering events, bringing together pharmaceutical companies, biotechnology developers, investors, and business development executives from around the world.

Dr. Fishman will be available for partnering discussions throughout the conference.

(Press release, Can-Fite BioPharma, NOV 6, 2026, View Source [SID1234674388])

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

On November 6, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported new translational data from its randomized Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The data are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting (SITC 2026), being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The analysis evaluated paired tumor biopsies collected at screening laparoscopy and at interval debulking surgery from patients in both arms of OVATION 2, using 21 immune markers assessed by cyclic immunofluorescence. The results show that the addition of IMNN-001 to standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) was primarily responsible for increased anti-tumoral T-cell activity, as measured by increases in the CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both the tumor and the stroma. Higher CD8+/Treg and CD8+/CD4+ ratios have been associated with improved patient outcomes in other studies. The chemotherapy component of the regimen contributed a complementary effect, supporting proinflammatory macrophage polarization and decreasing myeloid infiltration, particularly in the tumor.

These findings provide additional evidence that the combination of IMNN-001 with N/ACT favors the switch of the tumor microenvironment from immunologically "cold" to "hot," supporting both the activation and the persistence of a T-cell immune response while suppressing pro-tumor myeloid cells. The findings corroborate translational results previously reported from the Phase 1 OVATION 1 study and provide a mechanistic rationale for the clinical benefit observed in OVATION 2, in which IMNN-001 improved final median overall survival by 14.7 months (45.1 months versus 30.4 months) compared with the standard-of-care control arm and median progression-free survival by three months.

"This data provides a compelling immunological explanation for the survival benefit we observed in OVATION 2," said Stacy R. Lindborg, Ph.D., president and chief executive officer of IMUNON. "Seeing a consistent, treatment-driven shift in the tumor immune microenvironment in patient biopsies, rather than in a preclinical model, is an important validation of our TheraPlas platform. Presenting this work at SITC (Free SITC Whitepaper), the premier forum for cancer immunotherapy, reflects the growing scientific interest in our approach as we advance the pivotal Phase 3 OVATION 3 trial."

"The central challenge in epithelial ovarian cancer has been its highly immunosuppressive tumor microenvironment, which has limited the effectiveness of immune therapies such as checkpoint inhibitors," said Douglas V. Faller, M.D., Ph.D., chief medical officer of IMUNON. "What these paired serial patient biopsies show is that IMNN-001 delivers IL-12 where it is needed and dramatically remodels local immune balance in favor of the patient (from "cold" to immunologically "hot"), with minimal systemic IL-12 exposure and a highly favorable safety and tolerability profile. The complementary contributions of IMNN-001 and chemotherapy observed in this analysis help explain why this combination has translated into a survival benefit in the clinic."

The Phase 3 OVATION 3 trial (NCT06915025) is currently enrolling and is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer. The trial will also extend the immunological translational research program described in the poster.

Presentation Details

IMNN-001-mediated therapeutic delivery of IL-12 plasmid to tumor tissue and tumor microenvironment, promotes activation and persistence of T-cells which translates to a survival benefit in the clinic
Presenting author: Dr. Douglas Faller, IMUNON, Inc.
Abstract/Poster number: 478
Session: Poster Session 2, Saturday, November 7, 2026, 10 a.m.–2 p.m. and 6–8:10 p.m. MST
Location: Phoenix Convention Center, Phoenix, Arizona
The poster will be available on the Scientific Presentations section of the IMUNON website at www.imunon.com following the presentation.

About the OVATION 2 Study

The OVATION 2 Study (NCT03393884) was a randomized, controlled Phase 1/2 trial evaluating IMNN-001 (100 mg/m2 administered intraperitoneally weekly) in combination with standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin, compared with N/ACT alone, in 112 patients with newly diagnosed Stage III/IV epithelial ovarian cancer. The study included the collection of paired tumor tissue at screening laparoscopy and at interval debulking surgery to support translational research.

About the Phase 3 OVATION 3 Trial

The pivotal Phase 3 OVATION 3 trial is evaluating intraperitoneal IMNN-001 at 100 mg/m² in combination with standard-of-care neoadjuvant and adjuvant chemotherapy versus chemotherapy alone in patients with newly diagnosed Stage IIIB/C or IV epithelial ovarian, fallopian tube or primary peritoneal cancer. The trial is enrolling an all-comers population that includes both homologous recombination-deficient and homologous recombination-proficient patients; eligible patients who respond to first-line platinum-based chemotherapy will proceed to PARP inhibitor maintenance according to applicable guidelines and prescribing information. The primary endpoint is overall survival, with secondary endpoints including chemotherapy response score, surgical response score at interval debulking surgery, time to second-line treatment or death, and objective response rate.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer, and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

(Press release, IMUNON, NOV 6, 2026, View Source [SID1234674406])

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

On November 6, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), reported preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations highlight BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform and BriaPro’s BP-80 and TILsRx immunotherapy programs, including advances in engineered CD80 proteins.

"These findings provide additional preclinical support for our cellular immunotherapy and checkpoint inhibitor programs, including Bria-BRES+ in breast cancer and Bria-PROS+ in prostate cancer," stated William V. Williams, MD, BriaCell’s President and CEO. "The results support continued development of our immunotherapy pipeline across multiple cancer indications."

Highlights of the SITC (Free SITC Whitepaper) 2026 Presentations

BriaCell

Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Time: 12:15 – 1:45 PM, 5:30 – 7:00 PM MT

Key Findings:
Bria-OTS+ demonstrated broad innate and adaptive immune activation, including stimulating immune cells from patients with breast and prostate cancer. Priming and boosting enhanced cancer-cell killing across multiple tumor cell lines, while repeated tumor challenges demonstrated sustained cytotoxic activity. Activity was also confirmed in Bria-OTS+-activated immune cells derived from cancer patients.

BriaPro

Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Time: 12:00 – 1:30 PM, 6:40 – 8:10 PM MT

Key Findings:
BP-80 demonstrated CD28 co-stimulatory activity and counteracted CTLA-4-mediated inhibition in cell-based assays. In a four-week GLP nonhuman primate study, BP-80 was well tolerated, with no treatment-related pathological findings and a No Observed Effect Level (NOEL) of 50 mg/kg/dose, well above the predicted clinically active dose.

Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Time: 12:15 – 1:45 PM, 5:30 – 7:00 PM MT

Key Findings:
TILsRx-001, a B7-H3-targeting TILsRx construct with two CD80 extracellular domains (ECD), antagonized the immune inhibitory effect of PD-L1 in a cell-based surrogate assay. Engineered with two mutations in each CD80 ECD, TILsRx-001 demonstrated a 49-fold higher binding affinity for PD-L1 than the corresponding TILsRx construct without these CD80 mutations, supporting further development of TILsRx-001 as a tumor-targeted checkpoint inhibitor.

Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Time: 12:00 – 1:30 PM, 6:40 – 8:10 PM MT

Key Findings:
Structure-guided engineering generated a soluble CD80 variant (CD80-Fc) with more than 130-fold stronger PD-L1 binding than CD80-Fc with wild-type CD80 sequence. Multiple CD80 mutations enhanced PD-L1 binding with no or only minimal effect on CD28 affinity, supporting the development of CD80-based immunotherapies.

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, NOV 6, 2026, View Source [SID1234674422])

Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

On November 6, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager (TCE) with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These new data highlight that our logic-gated Switch-DARPin TCEs can address one of the central challenges in solid tumors: achieving potent anti-tumor activity while avoiding side-effects on healthy tissues that express the same targets. The clean in situ safety data on primary mesothelial cells and lung pleura is compelling and exactly the kind of evidence we need to support advancing MP0632 into IND-enabling studies in cancer indications co-expressing MSLN and EpCAM," said Martin Steegmaier, Ph.D., Chief Scientific Officer of Molecular Partners. He added: "These new data validate the potential of the Switch-DARPin platform to unlock tumor antigens so-far considered undruggable."

The SITC (Free SITC Whitepaper) poster outlines the following key findings:

Potent and selective tumor cell killing, with efficacy comparable to a clinical-stage benchmark T-cell engager but a substantially improved safety profile
Safe integration of CD2 co-stimulation, enabling sustained T-cell activity
No detectable impact on primary human mesothelial or epithelial cells and no evidence of mononuclear cell infiltration in the lung pleura of mice expressing human EpCAM and MSLN

These data provide preclinical proof-of-concept that logic-gated Switch-DARPins can selectively target TAAs considered undruggable for TCEs to date, turning MSLN and EpCAM into a "clean" target pair. These results build on previously presented data demonstrating regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tissue expressing only one antigen. In addition, the Switch-DARPin design allowed for safe use of potent co-stimulation for efficient tumor cell killing with low cytokine release profile.

Taken together, the preclinical data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, such as ovarian, endometrial, lung and pancreatic cancers.

Molecular Partners explores the broad therapeutic potential of its DARPin platforms, including Switch-DARPins inside and outside of oncology, through strategic partnerships and platform-derived spin-out opportunities, representing potential upside beyond its strategic focus on radiotherapeutics.

Details of the presentation

Title: MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM
Poster #1072, a Top 150 SITC (Free SITC Whitepaper) 2026 Abstract
Date & Time: 07 Nov 2026; 12:30-1:30 and 6:40-8:10 pm MT (poster viewing times)
Location: Phoenix Convention Center (PCC) – North Building – Lower-Level- Exhibition Halls 4-6

SITC takes place November 4-8 in Phoenix, AZ, USA.
The poster will be made available on Molecular Partners’ website after the presentation.

About MP0632

MP0632 is a next-generation, logic-gated T cell engager designed to activate T cells only when both MSLN and EpCAM are present. Its Switch-DARPin design enables reversible, dual-target-dependent un-masking of the CD3 binder for tumor-localized efficacy, while avoiding systemic T cell activity and limiting impact on healthy tissues. The built-in CD2 co-stimulation maintains potent and sustained tumor-localized T cell function.

(Press release, Molecular Partners, NOV 6, 2026, View Source [SID1234674407])

SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201 at SITC Annual Meeting

On November 6, 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported interim safety and efficacy results from the VICTORIA-01 Phase 1 clinical study of SOT201, a PD-1 targeting IL-15 immunocytokine, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting taking place November 6-8, 2026, in Phoenix, AZ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interim Phase 1 VICTORIA-01 data showed a 59% disease control rate with SOT201 among 22 patients with advanced solid tumors who had received a median of three prior treatment lines. Two patients achieved confirmed partial responses following prior checkpoint inhibitor therapy: an esophageal cancer response lasting 388 days and a cervical cancer response ongoing at 87 days. Most treatment-related adverse events were Grade 1 or 2. The findings supported a recommended dose of 80 µg/kg with a 20 µg/kg priming dose for further evaluation.

"Both IL-15 agonism and PD-1 inhibition have robust clinical validation in immuno-oncology, and SOT201 builds on this foundation by combining PD-1 and IL-15 mechanisms to reinvigorate antitumor T cell activities and to elicit deep antitumor immune responses," said Vivi Boura, M.D., Ph.D., chief medical officer of SOTIO. "These initial clinical data support continued evaluation of SOT201 in expanded patient cohorts, and we look forward to further characterizing its potential in challenging solid tumor types."

Presentation details are as follows:

Poster Title: "Interim safety and efficacy results of VICTORIA-01: A phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors"
Poster Number: 1180
Presenter: Dr. Aung Naing, Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, Texas
Date: Saturday, Nov. 7, 2026

In additional poster presentations at SITC (Free SITC Whitepaper), SOTIO will share research on the localization of tertiary lymphoid structures (TLS) in immune checkpoint-resistant cancer types, as well as the role of PD-L1+ macrophages in shaping TLS organization in ovarian cancer metastases.

(Press release, SOTIO, NOV 6, 2026, View Source [SID1234674423])